Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

分组1 - Mirum Pharmaceuticals reported a quarterly loss of $0.49 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.27, representing an earnings surprise of -81.48% [1] - The company posted revenues of $99.41 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 2.40%, and showing a year-over-year increase from $69.55 million [2] - Over the last four quarters, Mirum Pharmaceuticals has surpassed consensus revenue estimates three times [2] 分组2 - The stock has gained approximately 20.8% since the beginning of the year, outperforming the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.21 on revenues of $98.79 million, and for the current fiscal year, it is -$0.70 on revenues of $436.29 million [7] - The Medical - Biomedical and Genetics industry, to which Mirum Pharmaceuticals belongs, is currently ranked in the top 24% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]